SIRS-Lab GmbH and Biosite(R) Incorporated Announce Collaboration to Develop Diagnostics for Sepsis

Under the collaboration, SIRS-Lab will provide access to selectedbiomarkers for sepsis. Biosite will then make antibodies to thoseselected targets using the Company's proprietary antibody developmentprocess, which combines immunization of mice and phage display togenerate highly diverse libraries of Omniclonal(R) antibodies withhigh affinity and low cross-reactivity. The antibodies will be used togenerate assays for the measurement of the selected biomarker targetsin blood samples. Validated biomarkers will then be assessed forcommercialization potential, with high-value markers added toBiosite's product development process.

"We are delighted to work with Biosite to evaluate the potentialvalue of our sepsis biomarkers for clinical diagnostic applications,"said Dr. Stefan Russwurm, SIRS-Lab's chief executive officer. "Thisagreement combines the strengths of both companies: Biosite's provenantibody development and commercialization process for diagnosticproducts with our expertise in molecular medicine concerninginflammatory diseases."

"Our Biosite Discovery program is focused on diseases for whichrapid and accurate diagnostic tests are needed. Our antibodytechnology allows us to quickly and economically evaluate potentialbiomarkers for new tests," said Gunars Valkirs, Ph.D., senior vicepresident Biosite Discovery.

"We value SIRS-Lab's competence in the identification ofbiomarkers and we are pleased to have access to their intellectualproperty in the area of sepsis."

The financial terms of the agreement were not disclosed.

About SIRS-Lab

SIRS-Lab, a research driven diagnostics company located in theBioInstrumentation Center in Jena/Germany, is focused on theidentification, development and commercialization of novel,proprietary biomarkers. Those biomarkers provide a basis for thedevelopment of diagnostic systems for the early identification ofinflammatory/ immunological host responses as well as for the earlyidentification of the bacterial causes of infection. SIRS-Labs missionis the development of new diagnostic systems for clinical routinediagnostic and therapy monitoring of sepsis and acute inflammatorydiseases. Information on SIRS-Lab can be found athttp://www.sirs-lab.com/.

About Biosite Incorporated

Biosite Incorporated is a leading bio-medical companycommercializing proteomics discoveries for the advancement of medicaldiagnosis. The Company's products contribute to improvements inmedical care by aiding physicians in the diagnosis of criticaldiseases and health conditions.

Biosite's Triage(R) rapid diagnostics are used in approximately 50percent of U.S. hospitals and in more than 50 international markets.Information on Biosite can be found at www.biosite.com.

Except for the historical information presented herein, mattersdiscussed in this press release are forward-looking statements thatinvolve risks and uncertainties that could cause actual results todiffer materially from any future results, performance or achievementsexpressed or implied by such statements. Statements that are nothistorical facts, including but not limited to statements that arepreceded by, followed by, or that include the words "will";"believes"; "should"; "intends"; "anticipates"; "plans"; "expects";"estimates"; or similar statements are forward-looking statements.Forward looking statements include statements about the potentialbenefits of the collaboration and license agreement between Biositeand SIRS-Lab, Biosite's ability to generate antibody libraries ofselected targets and evaluate the diagnostic utility of the targets,Biosite's ability to develop and commercialize potential productsbased on selected targets and Biosite's ability to incorporate anylicensed targets into its product development pipeline. Risks thatshould be considered include risks and uncertainties regarding thediscovery and product development process generally, risks associatedwith the introduction of competitive products from companies withgreater capital and resources, uncertainties around the proprietarynature of the targets subject to the collaboration, expansion ordevelopment of a direct sales effort in domestic and internationalmarkets, and risks and expenses associated with litigation, contractdisputes, patent conflicts, product recalls, manufacturingconstraints, backlog, delays or inefficiencies, shipment problems,seasonal customer demand, the timing of significant orders, changes inreimbursement policies, regulatory changes, competitive pressures onaverage selling prices, and the other risks detailed in Biosite's mostrecent Annual Report on Form 10-K, as amended, Quarterly Report onForm 10-Q, and other SEC filings. Biosite disclaims, any intent orobligation to update these forward-looking statements. Copies ofBiosite's public disclosure filings are available from its investorrelations department.

Biosite(R), Omniclonal(R), Triage(R) and New Dimensions inDiagnosis(R) are registered trademarks of Biosite Incorporated. TheCompany's logo is a trademark of Biosite Incorporated.